The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProvexis Regulatory News (PXS)

Share Price Information for Provexis (PXS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.60
Bid: 0.55
Ask: 0.65
Change: 0.00 (0.00%)
Spread: 0.10 (18.182%)
Open: 0.60
High: 0.00
Low: 0.00
Prev. Close: 0.60
PXS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Draw Down of Funds and Issue of Equity

22 Jun 2010 07:00

RNS Number : 9915N
Provexis PLC
22 June 2010
 



22 June 2010

Provexis plc ("Provexis" or the "Company")

 

Draw Down of Funds and Issue of Equity

 

 

Provexis plc (PXS.L), which focuses on the discovery, development and licensing of scientifically-proven functional food, medical food and dietary supplement technologies, has raised net proceeds of £88,869 by drawing down on its Equity Financing Facility ("EFF") with Evolution Securities Limited ("ESL"). The EFF agreement was arranged by Darwin Strategic Limited ("Darwin") and was announced by Provexis on 31 March 2010. This draw down of funds is the first under the EFF agreement.

 

Under the terms of the EFF agreement the Company has allotted, conditional on admission to trading on AIM, 2,135,000 new ordinary shares of 0.1p each to ESL (the "New Provexis Shares"). The New Provexis Shares have been issued at 4.1625p per share and rank pari passu in all respects with the existing ordinary shares of 0.1p each in Provexis.

 

The draw down is the first undertaken by the Company since the announcement of the EFF and represents a premium of 2.8 per cent to the closing middle market price of the Company on 21 June 2010 (being the latest practicable date prior to this announcement). The net proceeds raised by the draw down were linked to the floor price set by the Directors at the time of draw down.

 

Application will be made to the London Stock Exchange for the 2,135,000 New Provexis Shares to be admitted to trading on AIM. It is expected that the admission will become effective and that trading in the New Provexis Shares will commence on 28 June 2010 ("Admission").

 

Following Admission, the Company's enlarged issued share capital will comprise 1,110,216,929 ordinary shares with voting rights. The Company does not hold any shares in treasury. This figure of 1,110,216,929 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FSA's Disclosure and Transparency Rules.

 

The Company and ESL have agreed to enter into a variation to the terms of the EFF agreement such that in relation to any future draw down under the EFF while the Company will continue to be obliged to specify a floor price in any draw down notice, the Company will have the right (with the agreement of ESL) to modify that floor price at any time during the relevant pricing period.

 

Following the granting of the requisite regulatory approvals to Darwin on 28 April 2010, each of the Company, ESL and Darwin have agreed to enter into a novation of the EFF from ESL to Darwin, such that all draw downs associated with the facility will be provided by Darwin.

 

About Darwin:

Darwin, a majority owned subsidiary of The Evolution Group, provides funding solutions for UK listed PLCs, including Equity Financing Facilities. Darwin's team has extensive experience in both corporate finance and secondary market trading, and can create bespoke funding solutions for companies beyond traditional debt and equity funding.

 

Enquiries:

Provexis plc

Stephen Moon, Chief Executive

Ian Ford, Finance Director

Tel: 01753 752290

Haggie Financial LLP

Peter Rigby/Juliet Tilley

Tel: 020 7417 8989

Evolution Securities Ltd

Sam Plumptre/Bobbie Hilliam

Tel: 020 7071 4317

Darwin Strategic Limited

Paul Hennigan/Anand Sambasivan

Tel: 020 3178 6174

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEFBMRTMBBTBIM
Date   Source Headline
10th Sep 20197:00 amRNSFinal Results
2nd Aug 20197:00 amRNSCollaboration agreement with By-Health Co., Ltd.
31st Jul 20197:00 amRNSTrading Update
27th Jun 20193:11 pmRNSTiming of trading update
12th Apr 20197:00 amRNSBoard changes
8th Mar 20199:44 amRNSHolding(s) in Company
31st Dec 20187:00 amRNSHalf-year Report
1st Nov 20181:00 pmRNSChange of Adviser and AIM Rule 17 notice
25th Oct 20181:55 pmRNSResult of AGM
16th Oct 20187:00 amRNSHolding(s) in Company
9th Oct 20184:25 pmRNSHolding(s) in Company
27th Sep 20187:10 amRNSFinal Results
27th Sep 20187:00 amRNSResults of Placing
4th Jul 20187:00 amRNSDirectorate Change - Frédéric Boned
25th Jun 20187:00 amRNSFruitflow®+ Omega-3 launch in Holland & Barrett
5th Feb 20182:16 pmRNSHolding(s) in Company
31st Jan 20188:21 amRNSDirectorate Change - Krijn Rietveld
2nd Jan 20187:00 amRNSGrant of Share Options
29th Dec 20177:09 amRNSHalf-year Report
4th Dec 20177:00 amRNSPatent application - Fruitflow and air pollution
10th Nov 20174:40 pmRNSSecond Price Monitoring Extn
10th Nov 20174:35 pmRNSPrice Monitoring Extension
2nd Nov 20174:41 pmRNSSecond Price Monitoring Extn
2nd Nov 20174:35 pmRNSPrice Monitoring Extension
31st Oct 20174:40 pmRNSSecond Price Monitoring Extn
31st Oct 20174:35 pmRNSPrice Monitoring Extension
3rd Oct 20174:10 pmRNSResult of AGM
26th Sep 20172:44 pmRNSStudy Publication
7th Sep 20177:00 amRNSPreliminary Results
4th Aug 20178:00 amRNSHolding(s) in Company
31st Jul 20177:59 amRNSResults of placing
28th Jul 20174:30 pmRNSFunding Update
3rd Jul 20177:00 amRNSFunding Update
9th Jun 20174:35 pmRNSPrice Monitoring Extension
5th Jun 20174:40 pmRNSSecond Price Monitoring Extn
5th Jun 20174:35 pmRNSPrice Monitoring Extension
19th May 20174:40 pmRNSSecond Price Monitoring Extn
19th May 20174:35 pmRNSPrice Monitoring Extension
10th May 20177:01 amRNSTrading Update
10th May 20177:00 amRNSResults of Placing
2nd May 20177:15 amRNSFunding Update
11th Apr 20174:40 pmRNSSecond Price Monitoring Extn
11th Apr 20174:35 pmRNSPrice Monitoring Extension
6th Apr 20177:00 amRNSBy-Health MOU and product launch for Fruitflow
8th Feb 20174:40 pmRNSSecond Price Monitoring Extn
8th Feb 20174:35 pmRNSPrice Monitoring Extension
30th Dec 20167:00 amRNSHalf-year Report
21st Dec 20164:41 pmRNSSecond Price Monitoring Extn
21st Dec 20164:35 pmRNSPrice Monitoring Extension
20th Dec 20167:00 amRNSFruitflow and Blood Pressure - second stage update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.